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OBJECTIVE — We investigated whether cardiovascular autonomic dysfunction was associ-
ated with glycemic control status over time in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — From 1999 to 2000, cardiovascular auto-
nomic nerve function testing (AFT) was performed on patients with type 2 diabetes (n  1,021)
and was followed-up in 2006 and February 2008. Tests for cardiovascular autonomic functions
measuredheartratevariabilityparameters(expiration-to-inspiration[E/I]ratio,responsestothe
Valsalva maneuver, and standing). AFT scores were determined from the results of the each test
as follows: 0 for normal and 1 for abnormal. We began with those who had a score of 0 and
assessed the changes in total score along with biannual A1C levels.
RESULTS — At follow-up, the development of cardiovascular autonomic dysfunction was
34.5% (E/I ratio 21.9%, Valsalva maneuver 77.8%, and posture 58.9%; n  783). The devel-
opment of cardiovascular autonomic dysfunction was higher in older patients (P  0.001); in
thosewithlongerdurationofdiabetes(P0.001);ofhypertension(P0.005),andofdiabetic
retinopathy (P  0.001); and in those who had higher levels of microalbuminuria (P  0.002).
Logisticregressionanalysisrevealedthatthedevelopmentofcardiovascularautonomicdysfunc-
tion was strongly associated with the mean A1C level during the follow-up period (mean A1C
9.0% vs. 7.0%, odds ratio 2.984, 95% CI 1.177–7.561; P  0.021).
CONCLUSIONS — The development of cardiovascular autonomic dysfunction was inde-
pendently associated with microvascular complications and glycemic control status during this
7.5-year follow-up in patients with type 2 diabetes.
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C
ardiovascular events are the main
cause of death among patients with
type 2 diabetes. Compared with
their counterparts without diabetes, the
relative risk of cardiovascular disease is
about three times greater in such patients
(1) and is associated with chronic diabe-
tes complications. Thus, diabetic auto-
nomic neuropathy (DAN) is closely
related to death caused by cardiovascular
diseaseandtoallothercausesofmortality
in these patients (2,3). A recent meta-
analysis also demonstrated that cardio-
vascular autonomic dysfunction, as
measured by heart rate variability, corre-
lated strongly with an increased risk of
silent myocardial ischemia and mortality
(4).
IncontrasttoothertypesofDAN,car-
diovascular autonomic neuropathy
(CAN) is a well-studied form of DAN
(2,5) because it has a well-established di-
agnostic test (6). Cardiovascular auto-
nomic nerve function testing (AFT) using
heart rate variability is sensitive, noninva-
sive,andreproducible;therefore,itiseas-
ily applicable for screening a large
number of diabetic patients even as out-
patients (2,6). The reported prevalence of
CAN varies dramatically from a low of
7.7% for patients with newly diagnosed
type 1 diabetes to a high of 90% among
potential recipients of a pancreas trans-
plant (2,7,8).
Most diabetes complications can be
prevented only if the glycemic status of
patients with diabetes can be maintained
within a nearly normal range (9). How-
ever, diabetes complications can develop
despite intensive glycemic control
(10,11). Poor glycemic control also plays
acentralroleinthedevelopmentandpro-
gression of autonomic dysfunction
(12,13). However, much remains to be
investigated about the natural course of
CAN and related risk factors for its pro-
gression in patients with type 2 diabetes.
If we could identify the contributing fac-
tors, early detection of CAN and prompt
interventionwouldbeclinicallymeaning-
ful for the prevention of adverse cardio-
vascular outcomes in patients with type 2
diabetes.
In this longitudinal cohort study, we
evaluated whether CAN would develop
according to glycemic control status
among patients with type 2 diabetes who
initially showed normal cardiovascular
autonomic nervous function. We also
studied the factors related to the develop-
ment of CAN.
RESEARCH DESIGN AND
METHODS—From January 1999 to
December 2000, AFT was performed on
patientsaged25–75yearswhohadtype2
diabetes at the university-afﬁliated dia-
betes center of St. Vincent’s Hospital in
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normal AFT results were recruited (n 
1,021) and received follow-up AFT from
January 2006 to February 2008. Patients
wereexcludediftheywere75yearsold,
if they were mentally ill or unable to un-
dertake the test, if they had arrhythmia
including atrial ﬁbrillation, or if they had
anysevereillness,suchasmalignancy,se-
vere infection, severe hypoglycemia, liver
cirrhosis,heartfailure,oralcoholism.Our
institutional ethics committee approved
the study.
At the beginning of the study, patient
height, body weight, and systolic and di-
astolic blood pressure were measured.
Hypertension was deﬁned as systolic
blood pressure 140 mmHg or diastolic
blood pressure 90 mmHg or as any use
of antihypertensive medications. Fasting
and postprandial plasma glucose levels
were measured using an automated enzy-
matic method and A1C levels were deter-
mined by high-performance liquid
chromatographywithareferencerangeof
4.4–6.4%. A1C levels were measured ev-
ery 6 months to evaluate the status of gly-
cemic control during the follow-up
period. Blood lipid concentrations for to-
tal cholesterol, triglycerides, and HDL
cholesterol were measured enzymatically
using an automatic analyzer (model 736-
40; Hitachi, Tokyo, Japan). Biochemical
laboratory tests were performed at base-
line and at the follow-up time points.
Cardiovascular AFT was performed
by one examiner using the Ewing
method, which includes tests for heart
rate variability, such as the expiration-to-
inspiration(E/I)ratioandresponsestothe
Valsalva maneuver and to a postural
change from lying to standing (2,6,14).
Patients were asked to fast for 12 h before
AFT and to avoid taking antidepressants,
neuroleptics, caffeine, nicotine, or anti-
histamines.TheE/Iratiowascalculatedas
the mean of the longest R-R interval dur-
ing expiration divided by the mean of the
shortest R-R interval during inspiration.
The ratio of postural change was the ratio
of the longest R-R interval during beats
20–40 after standing to the shortest R-R
interval during beats 5–25 after standing.
For the heart rate response to the Valsalva
maneuver, the ratio of the longest R-R in-
terval to the shortest R-R interval was
checkedduringforcedexhalationintothe
mouthpiece of a manometer to 40 mmHg
for 15 s (2,14).
An E/I ratio below the age-related ref-
erence value, a Valsalva ratio 1.2, and a
posture ratio 1.03 were considered ab-
normal (14). Each of the three items was
scored as 0 for normal or 1 for abnormal,
to a maximum score of 3. Normal AFT
was deﬁned as a score of 0, and CAN was
deﬁned on the basis of at least one abnor-
mal standard test. Progression of CAN
was deﬁned as an increase in a follow-up
AFTscorefromthebaselinevalue(ascore
of 0) to a score of 1–3; such patients were
designated the “progressor” group. “Non-
progressors” were deﬁned as type 2 dia-
betic patients whose CAN scores did not
show any increase at the follow-up time
point.
Theurinaryalbuminexcretion(UAE)
ratewasmeasuredbyenzymeimmunoas-
say from a single 24-h urine collection
(15) using immunoturbidimetry (Eiken,
Tokyo, Japan). Patients were classiﬁed
into three groups: those with no diabetic
nephropathy (UAE 20 g/min), those
withmicroalbuminuria(MAU)deﬁnedas
a UAE of 20–200 g/min, and those with
overt proteinuria with UAE 200 g/
min. Diabetic retinopathy was assessed
from retinal photographs at baseline, and
the ﬁndings were reviewed by one
ophthalmologist.
Statistical analyses
Alloftheresultsareexpressedasmeans
SD or median (range). Statistical analyses
were performed using SPSS statistical
software (SPSS, Chicago, IL). P  0.05
was considered signiﬁcant. Because of
their skewed distribution, triglyceride
and HDL cholesterol concentrations and
microalbuminuria levels were compared
after logarithmic transformation. 
2 tests
were used to test the univariate relation-
ships of categorical variables, and inde-
pendent Student’s t tests were used for
continuous variables. We used multiple
logistic regression analysis to test associa-
tions between the outcome (progression
of AFT at follow-up) and potential ex-
planatory variables. The relationships
were analyzed after adjustment for the
following risk factors: age, duration of
diabetes, presence of hypertension,
smoking, diabetic foot ulceration, and di-
abetic retinopathy and nephropathy. The
results are given as odds ratios with 95%
CIs.
RESULTS—Of the 1,021 patients who
had normal cardiovascular AFT results,
783 (76.7%) completed a follow-up AFT
evaluation (Fig. 1). At baseline, the total
study population consisted of 392 men
and 629 women with mean  SD age of
50.2  10.7 years. Duration of diabetes
was 7.1  6.5 years, and A1C level was
8.6  2.2%. The 783 participants who
wereevaluateddidnotdifferfromthe248
patients who were not assessed, with re-
spect to age (50.7  10.4 vs. 51.7 
11.6 years, P  0.190), sex ratio (P 
0.649), presence of hypertension (P 
0.279), duration of diabetes (7.7  6.7
vs. 7.4  7.7 years, P  0.390), or A1C
level (8.7  2.0% vs. 8.5  2.4%, P 
0.915). During follow-up, seven pa-
tients died: four women and three men.
Figure 1—Study enrollment and follow-up.
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patients, myocardial infarction in two
patients, cerebral hemorrhage in one
patient,andmalignancyintwopatients.
The median follow-up period was 7.5
years.
At follow-up, 307 (39.2%) patients
had hypertension and all of them were
takingantihypertensivemedication.Thir-
ty-two (10.4%) patients were treated for
hypertension with calcium channel
blockers, 6 (2.0%) with -blockers, 140
(45.6%)withACEinhibitorsorangioten-
sin receptor blockers, 4 (1.3%) with thia-
zides, and 125 (40.7%) with any
combination of antihypertensive agents.
Baseline sex ratios and BMIs were similar,
and there was no difference in the treat-
mentofdiabetes(P0.773)orhyperten-
sion (P  0.326) in the progressor and
nonprogressor groups. However, the pa-
tients with progression were older (P 
0.001) with a longer duration of diabetes
(P  0.001), more were smokers (P 
0.045), and more had hypertension (P 
0.001). Moreover, the progressor group
had higher levels of fasting glucose (P 
0.004),postprandialglucose(P0.010),
and microalbuminuria (P  0.002) than
patients without progression (Table 1).
However, there were no differences in to-
tal cholesterol, triglyceride, or HDL cho-
lesterol levels between the two groups.
The patients with progression also showed
higher frequencies of diabetic nephropa-
thy (P  0.004) and diabetic retinopathy
(P  0.001) during the observation pe-
riod than the patients in the nonprogres-
sor group (Table 1).
At follow-up, 270 patients (34.5%)
showed abnormal cardiovascular AFT
scores (total score 1, the progressor
group). The results of the deep breathing,
Valsalvamaneuver,andlying-to-standing
tests were abnormal in 59 (21.9%), 210
(77.8%), and 159 (58.9%) patients, re-
spectively. In terms of total score, 138
(51.1%) patients had a score of 1, 106
(39.3%) had a score of 2, and 26 (9.6%)
had a score of 3. The distribution of ab-
normal E/I ratio, Valsalva maneuver, and
postureratiosinpatientswithatotalscore
o f1( n  138) at follow-up was 12
(8.7%), 83 (60.1%), and 43 (31.2%) pa-
tients, respectively.
Even among the 133 patients with
newly diagnosed diabetes at baseline, 43
(32.3%) showed abnormal AFT results at
follow-up, with total scores of 1. These
includedanabnormalE/Iscorein4(9%),
an abnormal Valsalva ratio score in 34
(79%), and an abnormal posture score in
21 (49%) (Table 2).
Logistic regression analysis revealed
that the mean value of biannually mea-
sured A1C was correlated signiﬁcantly
with the future development of CAN.
Table 1—Clinical characteristics according to progression of CAN
Progressor Nonprogressor P value
n 270 513
Age (years) 53.2  9.7 48.8  9.8 0.001
Sex (male/female) 105/165 215/298 0.170
Duration (years) 8.30  6.9 6.27  5.7 0.001
BMI (kg/m
2) 25.1  3.6 24.7  3.2 0.195
Hypertension 124 (45.9) 183 (35.7) 0.005
Smoking 55 (20.3) 74 (14.4) 0.045
Retinopathy at baseline 97 (35.9) 101 (19.7) 0.001
Nephropathy at baseline 0.004
Normal 199 (73.7) 426 (83.0)
Microalbuminuria 55 (20.4) 74 (14.4)
Overt proteinuria 16 (5.9) 13 (2.6)
Diabetes treatment 0.773
Diet and exercise 13 (4.8) 22 (4.3)
Oral agents 150 (55.6) 289 (56.3)
Insulin 43 (15.9) 86 (16.8)
Insulin  oral agents 64 (23.7) 116 (22.6)
Baseline
FPG (mmol/l) 9.52  4.2 8.76  3.0 0.004
Creatinine (mol/l) 72  22 72  18 0.972
Total cholesterol (mmol/l) 4.73  0.9 4.74  1.2 0.827
Triglyceride (mmol/l) 1.54 (0.54–8.24) 1.50 (0.41–8.64) 0.995
HDL cholesterol (mmol/l) 10.6 (0.44–1.78) 1.09 (0.47–2.12) 0.110
A1C (%) 8.88  2.0 8.39  1.9 0.001
Postprandial glucose (mmol/l) 16.2  5.6 15.1  5.3 0.010
Microalbuminuria (g/min) 12.4 (0.5–2634) 10.0 (0.5–2398) 0.002
Follow-up
FPG (mmol/l) 8.55  3.1 8.34  2.8 0.331
Creatinine (mol/l) 90  65 81  21 0.006
Total cholesterol (mmol/l) 4.71  1.0 4.62  0.8 0.200
Triglyceride (mmol/l) 1.42 (0.34–9.15) 1.40 (0.32–8.03) 0.911
HDL cholesterol (mmol/l) 1.14 (0.34–2.79) 1.14 (0.59–2.43) 0.624
A1C (%) 8.33  1.7 8.03  1.6 0.017
Postprandial glucose (mmol/l) 14.4  4.8 13.6  4.9 0.024
Microalbuminuria (g/min) 17.3 (0.5–3620) 13.9 (5301.8) 0.004
Mean A1C (%) 8.4  1.4 7.9  1.3 0.001
Data are means  SD, n (%), or median (range). P  0.05 was considered signiﬁcant. FPG, fasting plasma
glucose.
Table 2—Changes in cardiovascular AFT results in the progressor group
Progressor group
Total Newly diagnosed diabetes
n 270 43
Abnormal E/I ratio 59 (21.9) 4 (9.3)
Abnormal Valsalva maneuver 210 (77.8) 34 (79.1)
Abnormal posture 159 (58.9) 21 (48.8)
Total score at follow-up
1 138 (51.1) 28 (65.1)
2 106 (39.3) 14 (32.6)
3 26 (9.6) 1 (2.3)
Data are n (%).
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A1C value was 7.0%, having a level of
11.0%wassigniﬁcantlyassociatedwith
the progression of CAN (Table 3). The
conventionalriskfactors,suchasage(P
0.001), diabetic retinopathy (P  0.036),
and diabetic nephropathy (P  0.035) at
baseline predicted the progression of
CAN after adjustments were made for
baseline age, hypertension, smoking
habit, and the duration of diabetes. Dura-
tionofdiabetesorhavingasmokinghabit
wasnotassociatedwiththeprogressionof
AFT.Inthisstudy,uncontrolledglycemic
status was an independent risk factor for
the development of CAN.
CONCLUSIONS —This was a longi-
tudinal observational study designed to
investigate factors that might inﬂuence
the progression of CAN in patients with
type 2 diabetes. We demonstrate that CAN
progressed according to glycemic control
statusandthatitwasassociatedwithpreex-
isting chronic diabetes complications.
Diabetes is an important risk factor
fordevelopmentofcardiovascularandce-
rebrovascular diseases (16,17). DAN is a
serious and common complication of di-
abetesassociatedwithanincreasedriskof
cardiovascular mortality. Many studies
have shown consistently that there is an
increased risk of cardiovascular mortality
among patients with an abnormal CAN
assessment, compared with those with
normal assessment (18,19). Therefore,
early detection of high-risk diabetic pa-
tients and aggressive intervention should
be promising therapeutic strategies.
In 2005, a consensus statement from
theAmericanDiabetesAssociation(ADA)
recommended the battery of tests for the
assessment of CAN including heart rate
variability (HRV), E/I ratio, response to
the Valsalva maneuver, and standing up
(2,14). HRV methods are age dependent
butindependentoftheintrinsicheartrate
(2,14,20).Untilnow,measuringHRVhas
been a standard screening method in the
diagnosis of autonomic dysfunction. AFT
is easy to perform and is a reproducible
test using a simple device at the patient’s
bedside (21,22).
There have been limited observations
with regard to the progression of CAN in
patients with type 2 diabetes. Poor glyce-
mic control plays a central role in its de-
velopment and progression (12,13).
Moreover, strict glycemic control can
slow the progression and delay the ap-
pearance of abnormal AFTs (10,23). In
theEuropeanDiabetes(EURODIAB)Pro-
spective Complication Study, the inci-
dence of neuropathy was 23.5%, and the
change in A1C value during a follow-up
periodof7yearswasindependentlyasso-
ciated with the incidence of neuropathy
(11). The Diabetes Control and Compli-
cations Trial (DCCT) Research Group
also documented that intensive therapy
can slow the progression and the devel-
opment of an abnormal autonomic test.
However, these well-performed prospec-
tive studies were only conducted on pa-
tients with type 1 diabetes.
Similar to the EURODIAB study, we
found that 	35% of our patients showed
progression of CAN. Even in the patients
with newly diagnosed type 2 diabetes,
	30% showed abnormal AFT results af-
ter7.5years.Glycemiccontrolwasanim-
portant risk indicator in this progression.
We used the mean A1C value, measured
every 6 months for 7.5 years, as a represen-
tative index of glycemic control status.
Blood glucose control, as determined by
A1C levels, seemed to be improved more
during follow-up in the progressor group
thaninthenonprogressorgroup.However,
the mean A1C values during the observa-
tion period were signiﬁcantly higher in the
progressor group. We suggest that, as for
type 1 diabetes, glycemic control could in-
ﬂuencethedevelopmentandprogressionof
CAN in patients with type 2 diabetes.
In addition, previous reports about
CAN were designed to test only the E/I
ratio or orthostatic hypotension. How-
ever, in our results, each of the three AFT
tests showed a different rate of progres-
sion; a partial measurement of AFT offers
only limited information about CAN.
With use of the ADA criteria for the diag-
nosis of CAN in this study, the frequency
of abnormal AFT results were, in order,
the Valsalva maneuver, posture, and the
E/IratioamongpatientswhoseinitialAFT
results were normal. We suggest that the
Valsalva ratio is the most sensitive param-
eter of the three values.
Interestingly, the duration of diabetes
was not signiﬁcantly associated with the
development of CAN. Although diabetes
duration has been reported to play an im-
portant role in patients with type 1 dia-
betes (12), the inﬂuence of diabetes
duration seems to play a less important
role in type 2 diabetes. Consistent with
previous studies, we found an association
between CAN and microvascular compli-
cations (24,25). CAN progression is cor-
relatedwithdiabeticretinopathy,diabetic
nephropathy, and an increased urinary
microalbuminexcretionrate.Thisﬁnding
suggests that clinicians should pay more
attention to patients with diabetic reti-
nopathy or nephropathy, over and above
the strict glycemic control required for
the prevention of CAN.
Thelimitationsofourstudyareasfol-
lows. First, there have been no normal
values established for the E/I ratio, Val-
salvamaneuver,andposturetestsspeciﬁc
to normal Korean subjects or to Korean
patients with diabetes. It remains to be
Table 3—Multiple logistic regression analysis
Odds ratio (95% CI) P value
Age (years) 0.001
40 1.000
41–50 1.787 (1.047–3.049) 0.033
51–60 2.679 (1.550–4.630) 0.001
60 3.867 (2.133–7.011) 0.001
Diabetes duration (years)
5 1.000 0.744
6–10 0.855 (0.585–1.249) 0.417
11–15 0.966 (0.607–1.538) 0.966
15 1.147 (0.620–2.122) 0.662
Hypertension (yes vs. no) 1.196 (0.857–1.667) 0.292
Smoking (yes vs. no) 1.173 (0.763–1.804) 0.466
Retinopathy (yes vs. no) 1.513 (1.028–2.226) 0.036
Diabetic nephropathy (yes vs. no) 1.515 (1.031–2.228) 0.035
Mean A1C (%) 0.001
7.0 1.000
7.01–9.0 1.138 (0.898–2.134) 0.141
9.01–11.0 2.565 (1.526–4.312) 0.001
11.0 2.752 (1.075–7.048) 0.035
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Western populations can be applied to
Korean subjects; however, we performed
AFT with the same method by one exam-
iner throughout. Second, tests of blood
pressure response to standing, blood pres-
sure response to a sustained handgrip, and
the presence of orthostatic hypotension
were not checked because these tests were
not available in our Diabetes Center from
1999 to 2000. However, each of the three
tests of cardiovascular autonomic function
used had a sensitivity and speciﬁcity of
90% (2). Moreover, the ADA suggests
thatthethreetestsusedhereadequatelyful-
ﬁll their requirements because of their reli-
ability, reproducibility, general mutual
correlation,andcorrelationwiththetestsof
peripheralsomaticnervefunctionandwell-
established normal values. Third, we could
not evaluate the clinical importance of the
progressionofCAN.However,ourongoing
follow-up studies should provide some in-
sight into this issue.
In summary, prolonged exposure to
uncontrolled hyperglycemic conditions
could predict future CAN, independent
ofthedurationofdiabetesamongpatients
at baseline. Cardiovascular AFT should
be monitored to pay attention to major
potential cardiovascular complications
even in asymptomatic patients, but espe-
cially among those for whom glycemic
control is not maintained adequately.
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